Liquid chromatographic determination of NSC 737664 (ABT-888: An inhibitor of poly(ADP-ribose) polymerase (PARP)) in plasma and urine in a phase 0 clinical trial

Journal of Liquid Chromatography and Related Technologies

Volumn 32, Issue 2, 2009, Pages 261-272

  Phillips, Lawrence R ^a   Hill, Kimberly D ^b   Majerova, Eva ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

ABT 888; PARP inhibitor; Phase 0 study

Indexed keywords

ACETONITRILE; ACIDS; BODY FLUIDS; ELECTROSPRAY IONIZATION; FORMIC ACID; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION OF LIQUIDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ORGANIC ACIDS; PLASMAS;

ABT-888; BENZIMIDAZOLE; C18 COLUMNS; CARBOXAMIDE; CHROMATOGRAPHIC DETERMINATIONS; CHROMATOGRAPHIC PEAKS; CHROMATOGRAPHIC SEPARATIONS; CLINICAL STUDIES; CLINICAL TRIALS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS; HUMAN PLASMAS; ION ELECTROSPRAY IONIZATIONS; PARP INHIBITOR; PHASE 0 STUDY; URINE LEVELS; UV DETECTIONS;

PHASE SEPARATION;

2 [2 METHYLPYRROLIDIN 2 YL] 1H BENZIMIDAZOLE 4 CARBOXAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NSC 737664; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG INHIBITION; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; POSITIVE ION ELECTROSPRAY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; URINALYSIS;

EID: 58149091184     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070802603351     Document Type: Article

References (12)

1. Curtin, N. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opin. Ther. Targets. 2007, 11 (6), 783-799 (Review).
2. De Murcia, G.; Menissier De Murcia, J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 1994, 19, 172-176.
3. Schreiber, V.; Dantzer, F.; Ame, J.C.; De Murcia, G. Poly(ADP-ribose): Novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7, 517-528.
4. Ratnam, K.; Low, J.A. Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin. Cancer Res. 2007, 13(5), 1383-1388 (Review).
5. Plummer, R.; Middleton, M.; Wilson, R.; Jones, C.; Evans, J.; Robson, L.; Steinfeldt, H.; Kaufman, R.; Reich, S.; Calvert, A.H. First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. J. Clin. Oncol. 2005, 23 (16 S), 3065.
6. Thomas, H.D.; Calabrese, C.R.; Batey, M.A.; Canan, S.; Hostomsky, Z.; Kyle, S.; Maegley, K.A.; Newell, D.R.; Skalitzky, D.; Wang, L.Z.; Webber, S.E.; Curtin, N.J. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 2007, 6 (3), 945-956.
7. Wernet, W.; Penning, T.D.; Giranda, V.L. Combination therapy with PARP inhibitors. United States Patent Application 20070265324 (January 17, 2007).
8. Donawho, C.K.; Luo, Y.; Luo, Y.; Penning, T.D.; Bauch, J.L.; Bouska, J.J.; Bontcheva-Diaz, V.D.; Cox, B.F.; De Weese, T.L.; Dillehay, L.E.; Ferguson, D.C.; Ghoreishi-Haack, N.S.; Grimm, D.R.; Guan, R.; Han, E.K.; Holley-Shanks, R.R.; Hristiv, B.; Idler, K.B.; Jarvis, K.; Johnson, E.F.; Kleinberg, L.R.; Klinghofer, V.; Lasko, L.M.; Liu, X.; Marsh, K.C.; McGonigal, T.P.; Meulbroek, J.A.; Olson, A.M.; Palma, J.P.; Rodriguez, L.E.; Shi, Y.; Stavropoulos, J.A.; Tsurutani, A.C.; Zhu, G.D.; Rosenberg, S.H.; Giranda, V.L.; Frost, D.J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13(9), 2728-2737.
9. Albert, J.M.; Cao, C.; Kim, K.W.; Willey, C.D.; Geng, L.; Xiao, D.; Wang, H.; Sandler, A.; Johnson, D.H.; Colevas, A.D.; Low, J.; Rothenberg, M.L.; Lu, B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 2007, 13 (10), 3033-3042.
10. Kummar, S.; Kinders, R.; Gutierrez, M.; Rubenstein, L.; Parchment, R.E.; Phillips, L.R.; Low, J.; Murgo, A.J.; Tomaszewski, J.E.; Doroshow, J.H. Inhibition of poly(ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial. J. Clin. Oncol. 2007, 25 (18S), 3518.
11. Kinders, R.; Parchment, R.E.; Ji, J.; Kummar, S.; Murgo, A.J.; Gutierrez, M.; Collins, J.; Rubinstein, L.; Pickeral, O.; Steinberg, S.M.; Yang, S.; Hollingshead, M.; Chen, A.; Helman, L.; Wiltrout, R.; Simpson, M.; Tomaszewski, J.E.; Doroshow, J.H. Phase 0 clinical trials in cancer drug development: From FDA guidance to clinical practice. Mol. Interv. 2007, 7 (6), 325-334.
12. Kummar, S.; Kinders, R.; Gutierrez, M.E.; Rubenstein, L.; Parchment, R.E.; Phillips, L.R.; Ji, J.; Monks, A.; Low, J.A.; Chen, A.; Murgo, A.J.; Collins, J.; Steinberg, S.M.; Eliopoulos, H.; Giranda, V.L.; Gordon, G.; Helman, L.; Wiltrout, R.; Tomaszewski, J.E.; Doroshow, J.H. Phase 0 clinical trial of the poly(ADP-ribose)polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol., submitted.